The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 901–1,000 of 2,716
Effective Long-Term Treatment of Cushing’s Disease with Pasireotide: A Case Report
Lü, L., Duan, L., Jin, Z., Lu, Z., & Gu, F. (2013) · Endocrine Practice · doi:10.4158/ep12296.cr · Cited by 18
Corticotropin-independent Cushing's Syndrome in Patients with Bilateral Adrenal Masses
Li, Z., Zhu, Y., Kong, C., Yin, L., Gao, Z., Zhao, W., & Gong, D.-X. (2010) · Urology · doi:10.1016/j.urology.2010.09.045 · Cited by 17
Chronic anovulation and the polycystic ovary syndrome
KASE, N. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003254.012 · Cited by 16
Antonelli, G., Padoan, A., Artusi, C., Marinova, M., Zaninotto, M., & Plebani, M. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.12.006 · Cited by 20
Neychev, V. K., Steinberg, S. M., Yang, L., Mehta, A. R., Nilubol, N., Keil, M. F., Nieman, L. K., Stratakis, C. A., & Kebebew, E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4605-1 · Cited by 19
“consensus statements on screening, diagnosis and treatment of CS; however, the complexity and heterogeneity of this condition continue to present a considerable management challenge, and establishing the best treatment modality for patients with CS is a work in progress.(1,4,5,13,15) The shortterm outcomes of various…”
BackgroundSelf-citationGlucocorticoid receptor polymorphisms influence muscle strength in Cushing's syndrome
Müller, L. M., Kienitz, T., Deutschbein, T., Riester, A., Hahner, S., Burger-Stritt, S., Berr, C. M., Oßwald, A., Braun, L., Rubinstein, G., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz052 · Cited by 17
Gendreitzig, P., Kunzel, H. E., Adolf, C., Handgriff, L., Müller, L., Holler, F., Sturm, L., Heinrich, D. A., Reincke, M., & Quinkler, M. O. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab099 · Cited by 18
“Reference values were similar to those suggested by the Endocrine Society Practice Guideline „Diagnosis of Cushing‟s syndrome‟ (32).”
MethodBancos, I., Hatipoğlu, B., Yuen, K. C. J., Chandramohan, L., Chaudhari, S., & Moraitis, A. G. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100256 · Cited by 24
Jurek, A., Krzesiński, P., Gielerak, G. G., Witek, P., Zieliński, G., Kazimierczak, A., Wierzbowski, R., Banak, M., & Uziębło‐Życzkowska, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751743 · Cited by 19
Raff, H. (2022) · Pituitary · doi:10.1007/s11102-022-01214-2 · Cited by 19
“Assessing late-night salivary cortisol (LNSC) is now a mainstay in the diagnosis of de novo neoplastic hypercortisolism (endogenous Cushing’s syndrome) primarily as a result of its prominence in the 2008 Endocrine Society guidelines [2].”
BackgroundKelley, K. D., & Aronowitz, P. B. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.12.006 · Cited by 19
Federal clinical practice guidelines on the diagnostics and treatment of adrenocortical cancer
Mel'nichenko, G. A., Stilidi, I. S., Alekseev, B. Y., Gorbunova, V. A., Beltsevich, D. G., Райхман, А. О., Kuznetsov, N. S., Zhukov, N. V., & Bokhyan, V. Y. (2014) · Problems of Endocrinology · doi:10.14341/probl201460251-67 · Cited by 19
“Существующие международные клинические рекомендации в отношении диагностики гиперкортицизма имеют достаточную доказательную базу [15].”
Fraser, R., Gower, D. B., Honour, J. W., Ingram, M. C., Kicman, A. T., Makin, H. L. J., & Stewart, P. M. (2010) · Springer eBooks · doi:10.1023/b135931_5 · Cited by 19
Self-citationLindholm, J. (2013) · Pituitary · doi:10.1007/s11102-013-0509-x · Cited by 18
“Several reviews on Cushing’s disease have been published within the last years [32–38].”
BackgroundCarrozza, C., Lapolla, R., Gervasoni, J., Rota, C. A., Locantore, P., Pontecorvi, A., Zuppi, C., & Persichilli, S. (2012) · HORMONES · doi:10.14310/horm.2002.1363 · Cited by 18
Bilateral adrenalectomy for Cushing's syndrome: Pros and cons
Verma, A., Prajapati, O., Mishra, A., et al. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.167544 · Cited by 17
“Although clinical manifestations include centripetal obesity, hypertension, impaired glucose tolerance, menstrual and sexual dysfunction, hirsutism, acne, striae, emotional liability, and osteoporosis but the most discriminating features are broad violaceous striae on atypical locations, children with short stature an…”
BackgroundThe cortisol awakening response is blunted in patients with active Cushing's disease
Roa, S. L. R., Elias, P. C. L., de Castro, M., & Moreira, A. C. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0982 · Cited by 17
Nakada, Y., Kageyama, K., Sugiyama, A., Desaki, R., Takayasu, S., Niioka, K., Murasawa, S., Ishigame, N., Asari, Y., Iwasaki, Y., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0369 · Cited by 17
Challenges in the Diagnosis and Management of Growth Hormone Deficiency in India
John, M. M., Koledova, E. B., Kumar, K. M. P., & Chaudhari, H. (2016) · International Journal of Endocrinology · doi:10.1155/2016/2967578 · Cited by 21
“, NS, SS homeobox-containing gene deficiency (SHOXD), and TS), there is a failure to gain height but the weight continues to be within normal centiles [43, 44].”
BackgroundDiurnal variation of cortisol, testosterone, and their ratio in apparently healthy males
Hayes, L. D., Grace, F., Kilgore, J. L., Young, D., & Baker, J. S. (2012) · Sport Scientific And Practical Aspects International Scientific Journal of Kinesiology · Cited by 29
Uvelius, E., Höglund, P., Valdemarsson, S. V., & Siesjö, P. (2018) · Pituitary · doi:10.1007/s11102-018-0902-6 · Cited by 17
Kreitschmann‐Andermahr, I., Siegel, S., Gammel, C., Campbell, K. K., Edwin, L., Grzywotz, A., Kuhna, V., Kołtowska‐Häggström, M., Müller, O. J., Buchfelder, M., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9014768 · Cited by 18
Screening for Cushing Syndrome at the Primary Care Level: What Every General Practitioner Must Know
Yorke, E., Atiase, Y., Akpalu, J., & Sarfo‐Kantanka, O. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1547358 · Cited by 27
“5μg/dl) is a reasonable cut-off to exclude the diagnosis of CS [31].”
BackgroundRoper, S. M. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa193 · Cited by 16
Diagnosis and treatment outcomes of Cushing’s disease during pregnancy
Sridharan, K., Sahoo, J., Palui, R., Patil, M., Kamalanathan, S., Ramesh, A., & Kubera, N. S. (2021) · Pituitary · doi:10.1007/s11102-021-01142-7 · Cited by 17
Ponzetto, F., Parasiliti‐Caprino, M., Settanni, F., Nonnato, A., Mengozzi, G., Ghigo, E., & Giordano, R. (2022) · Molecules · doi:10.3390/molecules28010248 · Cited by 16
“Although the application of the 18 ng/mL as cutoff value for the DST and LDDT screening could achieve 95% of sensitivity and 80% specificity for CS diagnosis [4], false-positive results could lead to additional follow-up examinations that are a matter of concern for both the healthcare system and the patients.”
MethodResultIssa, B. G., Hanna, F., Fryer, A. A., Ensah, G., Ebere, I., Marshall, D., & Keevil, B. G. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad242 · Cited by 20
Secondary hypertension as a cause of treatment resistance
Sudano, I., Suter, P. M., & Beuschlein, F. (2023) · Blood Pressure · doi:10.1080/08037051.2023.2224898 · Cited by 27
“• Patients with multiple and progressive features [25], particularly those that are more • predictive of Cushing’s syndrome such as between others facial plethora, Striae or proximal myopathy [24].”
BackgroundAnorexia nervosa and adrenal hormones: a systematic review and meta-analysis
Thavaraputta, S., Ungprasert, P., Witchel, S. F., & Fazeli, P. K. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad123 · Cited by 27
Endocrine causes of hypertension: literature review and practical approach
de Fréminville, J.-B., Amar, L., Azizi, M., & Mallart-Riancho, J. (2023) · Hypertension Research · doi:10.1038/s41440-023-01461-1 · Cited by 18
A Case Report of Cushing’s Disease Presenting as Hair Loss
Lefkowitz, E. G., Cossman, J. P., & Fournier, J. B. (2017) · Case Reports in Dermatology · doi:10.1159/000457898 · Cited by 16
Asari, Y., Kageyama, K., Nakada, Y., Tasso, M., Takayasu, S., Niioka, K., Ishigame, N., & Daimon, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s141345 · Cited by 16
“The primary cause of Cushing’s disease is the hypersecretion of adrenocorticotropic hormone (ACTH) from a pituitary adenoma.(1,2) ACTH then in turn stimulates the release of glucocorticoids from the adrenal glands.”
Adrenal disorders in pregnancy, labour and postpartum – an overview
Manoharan, M., Sinha, P., & Sibtain, S. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1648395 · Cited by 18
“Therefore, UFC cannot be considered as a reliable marker after the first trimester, unless levels are increased at least 2- to 3-fold above the upper limit of normal values (Nieman et al. 2008).”
BackgroundAdrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess
Kelsall, A., Iqbal, A., & Newell-Price, J. D. C. (2020) · Gland Surgery · doi:10.21037/gs.2019.11.19 · Cited by 20
“In this review we avoid the term subclinical CS and instead we use MCE, defined as mild hypercortisolism with AI but in the absence of classical clinical features of CS (7).”
MethodSelf-citationFehrenbach, U., Jadan, A., Auer, T. A., et al. (2020) · The Neuroradiology Journal · doi:10.1177/1971400920937843 · Cited by 16
“It has been postulated that in obesity, the entire hypothalamic-pituitary-adrenal axis is activated.(23) Enlargement of the pituitary gland in obese individuals as shown in our study could be a morphological correlate indicating dysfunction in the hypothalamic-pituitary-adrenal axis.”
BackgroundHyperandrogenismus, adrenale Dysfunktion und Hirsutismus
Makrantonaki, E., & Zouboulis, C. C. (2020) · Der Hautarzt · doi:10.1007/s00105-020-04677-1 · Cited by 19
Qiao, J., Li, J., Zhang, W., Wang, C., Li, J., Jiang, S., Tan, H., Chen, Y., Liu, H., Cai, B., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0837 · Cited by 18
“CUSHING’S SYNDROME (CS) is one of the most challenging diseases for endocrinologists, undoubtedly because the clinical manifestations are often nonspecific, and a single diagnostic test combining an optimal sensi‐ tivity (SE) and specificity (SP) for hypercortisolism and the determination of its etiology is unavailabl…”
BackgroundWang, W., Wang, J., Shen, C., Zhu, S., Gao, Y., & Zhang, J. (2021) · BioMed Research International · doi:10.1155/2021/6635594 · Cited by 22
“8μg/dL after LDDST, according to the criteria of the Endocrine Society clinical practice guidelines [20].”
BackgroundMethodInfluentialEvaluating Patients for Secondary Causes of Osteoporosis
Lewiecki, E. M. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00717-y · Cited by 20
Bukan, A., Dere, H. B., Jadhav, S., Kasaliwal, R., Budyal, S. R., Shivane, V. K., Lila, A. R., Bandgar, T., & Shah, N. S. (2014) · Endocrine Practice · doi:10.4158/ep14186.or · Cited by 16
Galiana, P. A., Fajardo, C., Suárez, P. A. R., Gómez-Vela, J., Escrivá, C., & Rovira-Lillo, V. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.09.009 · Cited by 18
Glucocorticoid Regulation of Food-Choice Behavior in Humans: Evidence from Cushing's Syndrome
Moeller, S. J., Couto, L., Cohen, V. V., Lalazar, Y., Makotkine, I., Williams, N., Yehuda, R., Goldstein, R. Z., & Geer, E. B. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00021 · Cited by 18
Bassareo, P. P., Fanos, V., Zaffanello, M., & Mercuro, G. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.103 · Cited by 17
Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing’s syndrome
Belaya, Z. E., Iljin, A. V., Mel'nichenko, G. A., Solodovnikov, A. G., Rozhinskaya, L. Y., Dzeranova, L. K., & Dedov, I. I. (2016) · BoneKEy Reports · doi:10.1038/bonekey.2016.42 · Cited by 16
“4 nmol l (1))(20) was independently followed by DST (cutoff value forsuppression: 50 nmol l (1)).(19) Any patients with discordant results from the initial evaluations underwent an additional third or fourth test: 24hUFC (reference range 60–413 nmol per 24 h) and/or awake serum cortisol at 2300 hours (reference range…”
MethodWang, D., Ji, Z., Li, H., & Zhang, Y. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170531 · Cited by 19
Sugiura, M., Imamura, Y., Kawamura, K., Yamamoto, S., Sazuka, T., Nakamura, K., Sakamoto, S., Nagano, H., Koide, H., Tanaka, T., et al. (2018) · International Journal of Urology · doi:10.1111/iju.13566 · Cited by 16
Dynamic changes of central thyroid functions in the management of Cushing's syndrome
Doğanşen, S. Ç., Yalın, G. Y., Canbaz, B., Tanrıkulu, S., & Yarman, S. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000019 · Cited by 17
“The diagnosis of CS was confirmed by failure to suppress plasma cortisol levels after the administration of 1-mgovernight and low-dose dexamethasone suppression tests (48 hours, 2 mg/day) in accordance with the current guideline (21).”
MethodAdipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI)
Babińska, A., Kaszubowski, M. F., & Sworczak, K. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0066 · Cited by 16
“The Endocrine Society recommended to consider 50 nmol/L serum cortisol after the 1 mg DXM suppression test as a threshold for CS diagnosis [34, 43-45].”
MethodZhang, X., Liao, H., Zhu, X., Shi, D., & Chen, X. (2019) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-019-2262-2 · Cited by 16
Dysregulation of resting-state functional connectivity in patients with Cushing’s disease
Wang, X., Zhou, T., Wang, P., Zhang, L., Feng, S., Meng, X., Yu, X., & Zhang, Y. (2019) · Neuroradiology · doi:10.1007/s00234-019-02223-y · Cited by 16
Vieira-Corrêa, M., Giorgi, R. B., de Oliveira, K. C., Hayashi, L. F., Costa‐Barbosa, F. A., & Kater, C. E. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01104-8 · Cited by 20
Das, L., Bhansali, A. K., Pivonello, R., Dutta, P. R., Bhadada, S. K., Ahuja, C. K., Mavuduru, R. S., Kumar, S., Behera, A., Saikia, U. N., et al. (2020) · Pituitary · doi:10.1007/s11102-020-01047-x · Cited by 18
Cyclin A in nonfunctioning pituitary adenomas
Lamback, E. B., Guterres, A., Barbosa, M. Á., Lima, C. H. D. A., Silva, D. A., Camacho, A. H. D. S., Chimelli, L. M. C., Kasuki, L., & Gadelha, M. R. (2020) · Endocrine · doi:10.1007/s12020-020-02402-5 · Cited by 16
Nonalcoholic fatty liver disease in subjects with adrenal incidentaloma
Papanastasiou, L., Παππά, Θ., Samara, C., Apostolopoulou, G., Tsiavos, V., Markou, Α., Alexandraki, K., Piaditis, G. P., Chrousos, G. P., & Kaltsas, G. (2012) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2012.02707.x · Cited by 19
Cushing’s Syndrome: Diagnosis and Treatment
Bhansali, A., & Gogate, Y. (2015) · Springer eBooks · doi:10.1007/978-81-322-2398-6_5 · Cited by 15
Hyperandrogenism, Hirsutism, and Polycystic Ovary Syndrome
Rosenfield, R. L., Barnes, R. B., & Ehrmann, D. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00133-5 · Cited by 17
Neurosurgical treatment of Cushing disease
Sheth, S. A., Bourne, S. K., Tritos, N. A., & Swearingen, B. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.006 · Cited by 15
Association between Sleep Duration and 24-Hour Urine Free Cortisol in the MrOS Sleep Study
Rao, M. N., Blackwell, T., Redline, S., Punjabi, N. M., Barrett-Connor, E., Neylan, T. C., Stone, K. L., & Osteoporotic Fractures in Men (MrOS) Study Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0075205 · Cited by 15
“Among these 342 participants, 17 were excluded from the analysis; 2 were taking prednisone, which affects the measurement of UFC, and 15 had 24-hour UFC data that was pathologically elevated or low [20–22].”
BackgroundSeastedt, K. P., Alyateem, G., Pittala, K., Steinberg, S. M., Schrump, D. S., Nieman, L. K., & Hoang, C. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24739 · Cited by 16
Self-citationRacial Disparities in Acromegaly and Cushing’s Disease: A Referral Center Study in 241 Patients
Ioachimescu, A. G., Goswami, N., Handa, T., Pappy, A. L., Veledar, E., & Oyesiku, N. M. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab176 · Cited by 15
“We performed a retrospective chart review to confirm the preoperative biochemical diagnosis of ACM and CD according to the most recent Endocrine Society guidelines [12, 13].”
Arterial hypertension and chronic kidney disease: consensus statement on patient management
Chazova, I. E., Кislyak, O. A., Podzolkov, V. I., Bragina, A. E., Анатольевна, С. О., Solntseva, T. D., Elfimova, E. M., Солтановна, В. З., Fomin, V. V., & Mironova, O. I. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2023-1-5-19 · Cited by 25
Morais, J. B. S., Cruz, K. J. C., de Oliveira, A. R. S., Cardoso, B. E. P., Dias, T. M. D. S., Melo, S. R. D. S., dos Santos, L. R., Severo, J. S., de Freitas, S. T., Henriques, G. S., et al. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03639-7 · Cited by 19
“It was conducted in three stages [47] using the function created by [48]: (1) estimation of a regression model where the variable of interest (to be imputed) was the response variable and the remaining variables collected were the explanatory ones, (2) estimation of the value of the variable of…”
MethodFlowers, K. C., & Shipman, K. E. (2023) · Diagnostics · doi:10.3390/diagnostics13081415 · Cited by 22
“Midnight plasma total cortisol analysis is a second line test for Cushing syndrome as it is impractical and stressful to admit a person to fall asleep and then be bled in the hospital [1].”
BackgroundInfluentialSerum cortisol assay performance following the 1 mg overnight dexamethasone suppression test
Atkins, J. S., Hawley, J. M., Owen, L. J., Clayton, J. C., Scargill, J., & Keevil, B. G. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231179560 · Cited by 16
“1,10 Individuals that fail to suppress cortisol are indicated for further investigations, including further screening tests, high-dose suppression tests, imaging, or biopsy.”
BackgroundCui, Q., Liu, X., Sun, Q., Sun, W., Zheng, H., He, M., Zhang, Z., Ma, Z., Shen, M., Shou, X., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03405-8 · Cited by 15
Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease
Rebollar‐Vega, R., Zuarth-Vázquez, J. M., & Hernández-Ramírez, L. C. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102899 · Cited by 17
PAM variants in patients with thyrotrophinomas, cyclical Cushing’s disease and prolactinomas
Sousa, S. M. C. D., Shen, A., Yates, C. J., Clifton-Bligh, R. J., Santoreneos, S., King, J. A. J., Toubia, J., Trivellin, G., Lania, A. G., Stratakis, C. A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1305606 · Cited by 17
“Cyclical Cushing ’ s disease was de fi ned by biochemical documentation of episodic cortisol excess interspersed by periods of normal or low cortisol secretion (8).”
BackgroundDelibaşı, T., Karbek, B., Bozkurt, N. Ç., Çakır, E., Güngüneş, A., Ünsal, Ö. Ö., Aslan, M. S., & Çakal, E. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000053 · Cited by 16
Salivary cortisol and the diagnosis of Cushing’s syndrome: a coming of age
Raff, H. (2012) · Endocrine · doi:10.1007/s12020-012-9661-8 · Cited by 15
“The theory behind the test and its execution has been exhaustively reviewed and is now widely accepted [3, 4].”
BackgroundSystemic therapy of Cushing’s syndrome
Eckstein, N., Haas, B., Hass, M. D. S., & Pfeifer, V. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0122-8 · Cited by 22
“This diagnosis flow-scheme also is reflected in current international text books [64] and for instance in the clinical practice guidelines of the endocrine society [65]:”
MethodCushing Disease Presenting as Primary Psychiatric Illness: A Case Report and Literature Review
Rasmussen, S. A., Rosebush, P. I., Smyth, H. S., & Mazurek, M. F. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000113 · Cited by 22
Ectopic Adrenocorticotropic Hormone–Secreting Pituitary Adenomas: An Underestimated Entity
Knappe, U. J., Jaspers, C., Buschsieweke, D., Reinbold, W., Al-Omari, A., Saeger, W., Ehlenz, K., Mann, W. A., Kann, P. H., & Feldkamp, J. (2017) · Neurosurgery · doi:10.1227/neu.0000000000001319 · Cited by 16
Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities
Yao, A., Balchandani, P., & Shrivastava, R. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.04.128 · Cited by 15
Lang, M., Habboub, G., Moon, D., Bandyopadhyay, A., da Silva, D. R. P., Kennedy, L., Kshettry, V. R., & Recinos, P. F. (2018) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0038-1642032 · Cited by 16
Remission of hypertension after surgical cure of Cushing's syndrome
Jha, S., Sinaii, N., McGlotten, R., & Nieman, L. K. (2019) · Clinical Endocrinology · doi:10.1111/cen.14129 · Cited by 15
Self-citationCiato, D., & Albani, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00021 · Cited by 16
Elder, C. J., Vilela, R., Johnson, T. N., Taylor, R. N., Kemp, E. H., Keevil, B. G., Cross, A. S., Ross, R. J. M., & Wright, N. P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa323 · Cited by 17
“Salivary cortisol is a validated and well-established alternative to invasive glucocorticoid sampling (11).”
BackgroundRecovery of hypothalamic‐pituitary‐adrenal axis in paediatric Cushing disease
Tatsi, C., Neely, M. L., Flippo, C. L., Bompou, M. E., Keil, M. F., & Stratakis, C. A. (2020) · Clinical Endocrinology · doi:10.1111/cen.14300 · Cited by 21
Ghorbani, M., Akbari, H., Griessenauer, C. J., Wipplinger, C., Dastmalchi, A., Malek, M., Heydari, I., Mollahoseini, R., & Khamseh, M. E. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05299 · Cited by 17
“IPSS is now applied as a standard diagnostic test in patients with suspected Cushing's disease who have either had inconclusive biochemical results or negative MRIs [26, 27, 28].”
MethodDutta, A., Gupta, N., Walia, R., Bhansali, A. K., Dutta, P. R., Bhadada, S. K., Pivonello, R., Ahuja, C. K., Dhandapani, S., Hajela, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01495-z · Cited by 15
Thompson, L. H., Ranstam, J., Almquist, M., Nordenström, E., & Bergenfelz, A. O. J. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-06214-0 · Cited by 16
“Most studies agree that non-functioning adrenocortical adenoma and ACS rarely progress to CS [3, 7, 32].”
BackgroundWhat to Do with Incidentally Discovered Pituitary Abnormalities?
Langlois, F., & Fleseriu, M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.015 · Cited by 17
Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19
Berlińska, A., Świątkowska−Stodulska, R., & Sworczak, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.711612 · Cited by 16
Ojeda, C. M., Santos, V. G. D., Álvaro, J. L., Ruz‐Caracuel, I., Pian, H. G., Dehesa, A. S., Revilla, F. J. B., & Castro, M. A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01836-0 · Cited by 15
Varricchio, L., Geer, E. B., Martelli, F., Mazzarini, M., Funnell, A. P. W., Bieker, J. J., Papayannopoulou, T., & Migliaccio, A. R. (2022) · Haematologica · doi:10.3324/haematol.2021.280542 · Cited by 15
“9 Cushing disease is characterized not only by excess levels of circulating gluco-corticoids, but also by fl attened cortisol diurnal rhythms and resistance to cortisol suppression by exogenous glucocorticoids.”
Fukuoka, H., Takeuchi, T., Matsumoto, R., Bando, H., Suda, K., Nishizawa, H., Takahashi, M., Hirota, Y., Iguchi, G., & Takahashi, Y. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0102 · Cited by 15
“The low-dose dexamethasone suppression test (LDDST) was performed as described previously [18, 21, 22].”
MethodBenign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids
Yoon, V., Heyliger, A., Maekawa, T., Sasano, H., Carrick, K. S., Woodruff, S. L., Rabaglia, J. L., Auchus, R. J., & Ghayee, H. K. (2013) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-13-0042 · Cited by 15
Childhood Cushing Disease: A Challenge in Diagnosis and Management
Shah, N. S., & Lila, A. R. (2011) · Hormone Research in Paediatrics · doi:10.1159/000329173 · Cited by 17
Kageyama, K., Oki, Y., Nigawara, T., Suda, T., & Daimon, M. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0120 · Cited by 17
Steffensen, C., Thomsen, H. H., Dekkers, O. M., Christiansen, J. S., Rungby, J., & Jørgensen, J. O. L. (2016) · Clinical Endocrinology · doi:10.1111/cen.13071 · Cited by 14
Radvany, M. G., Quiñones‐Hinojosa, A., Gallia, G. L., Wand, G. S., & Salvatori, R. (2016) · Endocrine Practice · doi:10.4158/ep161266.or · Cited by 15
Witek, P., Zieliński, G., Szamotulska, K., Witek, J., & Kamiński, G. (2015) · Endokrynologia Polska · doi:10.5603/ep.a2016.0034 · Cited by 17
Великанова, Л. И., Геннадьевна, С. Е., Obedkova, E. V., Krivokhizhina, N. S., Ривгатовна, Ш. З., Grigoryan, K., Povarov, V. G., & Москвин, А. Л. (2016) · Journal of Analytical Chemistry · doi:10.1134/s1061934816070169 · Cited by 15
IS THERE A ROLE OF ACTH IN INCREASED CHOROIDAL THICKNESS IN CUSHING SYNDROME?
Karaca, Ç., Karaca, Z., Kahraman, N., Sırakaya, E., Öner, A., & Mirza, G. E. (2016) · Retina · doi:10.1097/iae.0000000000001198 · Cited by 17
Evaluation of Endocrine Function
Guber, H. A., & Farag, A. F. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0974-2.00024-5 · Cited by 19
The Recovery of Hypothalamic-Pituitary-Adrenal Axis Is Rapid in Subclinical Cushing Syndrome
Kim, H. K., Yoon, J. H., Jeong, Y. A., & Kang, H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.4.592 · Cited by 15
Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma
Lopez, A.-G., Fraissinet, F., Lefèbvre, H., Brunel, V., & Ziegler, F. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.11.006 · Cited by 15
Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas
Aydın, S., Çomunoğlu, N., Ahmedov, M. L., Korkmaz, Ö. P., Öz, B., Kadıoğlu, P., Gazioğlu, N., & Tanrıöver, N. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.06.217 · Cited by 17
Lania, A. G., & Beck‐Peccoz, P. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.009 · Cited by 15
Белая, Ж. Е., Рожинская, Л. Я., Mel'nichenko, G. A., et al. (2013) · Problems of Endocrinology · doi:10.14341/probl20135943-10 · Cited by 15
“…АКТГ-зависимый ЭГ (АКТГ>10 нг/мл; уровень свободно-го кортизола в суточной моче выше референсных значений, высокое содержание вечернего кортизола в сыворотке крови, отрицательная малая проба с дексаметазоном (<50 нмоль/л) [19, 20] и/или высо-кое содержание свободного кортизола в слюне [21].”
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.